REG - Renalytix PLC - Investor Presentation and Revised Revenue Guidance

RenalytixAnnouncement

23/09/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250923:nRSW3385Aa&default-theme=true

RNS Number : 3385A  Renalytix PLC  23 September 2025

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law
by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the Company's obligations under Article 17 of
MAR.

 

Renalytix plc

("Renalytix" or the "Company")

 

Investor Presentation and Revised Revenue Guidance

 

Revised forward guidance on expected long-term increase in revenue

 

LONDON and NEW YORK, 23 September 2025 - Renalytix plc (LSE: RENX) (OTCQB:
RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the
only FDA-approved and Medicare reimbursed prognostic test to support
early-stage risk assessment in chronic kidney disease, announces that an
updated corporate presentation will be available today for download from the
Company's website at https://investors.renalytix.com/presentations/
(https://investors.renalytix.com/presentations/) .

 

The corporate presentation includes revised forward guidance on the Company's
expected revenue: $8.4m in FY26, $19.0m in FY27 and $42.0m in FY28 with the
later years of FY27 and FY28 reflecting the anticipated positive revenue
impact from Renalytix's recently announced
(https://www.londonstockexchange.com/news-article/RENX/tempus-ai-inc-collaboration-agreement/17230023)
collaboration agreement with Tempus AI, Inc. (Nasdaq: TEM) ("Tempus"). This
revenue guidance compares to a prior outlook through FY27 calling for $8.5m in
FY26, and $17.5m for FY27 as provided in the Company's Half Year Report on 18
March 2025.

 

The Board of Directors are currently considering the long-term positive impact
of the Tempus collaboration and the Company will provide further updates
regarding forward revenue guidance as appropriate, as the two parties execute
implementation into hospital systems and other healthcare providers.

 

For further information, please contact:

 

 Renalytix plc                                     www.renalytix.com (http://www.renalytix.com)
 James McCullough, CEO                             Via Walbrook PR

 SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)                   Tel: +44 (0)20 3470 0470
 Jeff Keating / David Hignell (Corporate Finance)

 Vadim Alexandre (Corporate Broking)

 Oberon Capital (Joint Broker)                     Tel: +44 (0)20 3179 5300
 Mike Seabrook / Nick Lovering / Aimee McCusker

 Walbrook PR Limited                               Tel: 020 7933 8780 or renalytix@walbrookpr.com
                                                   (mailto:renalytix@walbrookpr.com)
 Paul McManus / Alice Woodings                     Mob: 07980 541 893 / 07407 804 654

 

About Renalytix (www.renalytix.com)

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in
vitro diagnostics company, focused on optimizing clinical management of kidney
disease to drive improved patient outcomes. Renalytix has received FDA
approval and Medicare reimbursement for kidneyintelX.dkd which is now offered
commercially in the United States.

 

Unrecognized and uncontrolled kidney disease remains one of the largest
barriers to controlling cost and suffering in the United States and the United
Kingdom's medical system, affecting over 14 million and 8 million people,
respectively. After five years of development and clinical validation,
kidneyintelX.dkd is the only FDA-approved and Medicare reimbursed prognostic
tool capable of understanding a patient's risk with kidney disease early where
treatment has maximal effect. kidneyintelX.dkd is now being deployed across
large physician group practices and health systems in select regions of the
United States.

 

The over 15,000 patients that have been tested by kidneyintelX.dkd have
produced a substantial body of real-world performance data. In patient
populations where kidneyintelX.dkd has been deployed, a demonstrated and
significant increase in diagnosis, prognosis, and treatment rates have been
recorded. kidneyintelX.dkd now has full reimbursement established by Medicare,
the largest insurance payer in the United States, at $950 per reportable
result. kidneyintelX.dkd is also recommended for use in the international
chronic kidney disease clinical guidelines (KDIGO).

 

KidneyIntelX is based on technology developed by Mount Sinai faculty and
licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and
equity owners in the Company. In addition, the Icahn School of Medicine at
Mount Sinai has equity ownership in Renalytix. For information about the
kidneyintelX,dkd test, visit kidneyintelx.com (http://kidneyintelx.com/) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSELEFEEISEIU